Second death linked to vaping reported in Oregon

A second death, this time in Oregon, has been linked e-cigarette use after a patient was diagnosed with a severe respiratory illness.

The death, which was recorded in July, is the second such case recently reported, with one other death in Illinois linked to e-cigarette use, or vaping. The deaths come amid an outbreak of lung disease illnesses across with the nation, with more than 200 cases reported by the end of August. Patients have checked into hospitals with symptoms ranging from shortness of breath, cough, chest pain, vomiting, diarrhea, fatigue, fever or weight loss.

The CDC and several states are investigating the cause of the illnesses, though vaping is likely to blame. It is unknown if specific products or types of devices are causing the illnesses.

"We don’t yet know the exact cause of these illnesses—whether they’re caused by contaminants, ingredients in the liquid or something else, such as the device itself," Ann Thomas, MD, public health physician at OHA’s Public Health Division, said in a statement about the vaping-related death.

The person who died in Oregon had recently used an e-cigarette containing cannabis purchased from a cannabis dispensary, which are legal in the state. The revelation that the products were purchased legally raises questions that other illnesses around the country have been linked to vape oils and juices that were modified or purchased off the street instead of a legal distributor.

Recent studies have focused on the safety of vaping, but no federal review of such products has been conducted.

Amy Baxter

Amy joined TriMed Media as a Senior Writer for HealthExec after covering home care for three years. When not writing about all things healthcare, she fulfills her lifelong dream of becoming a pirate by sailing in regattas and enjoying rum. Fun fact: she sailed 333 miles across Lake Michigan in the Chicago Yacht Club "Race to Mackinac."

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.